Form D · Biotechnology
Akelos, Inc.
New York, NY · CIK 0001760186
Offering snapshot reported Mar 16, 2026 · SEC filing
- Reported sold
- $1.49M Indefinite offering
- Investors reported
- 81 Form D · investor count
- Minimum accepted
- $13.8K Reported outside-investor minimum
- First sale
- Mar 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 16, 2026 | Initial | $1,486,000 | No comparison | 81 | SEC filing |
| Oct 28, 2022 | Initial | $5,500 | No comparison | 1 | SEC filing |
| Feb 5, 2019 | Initial | $25,000 | No comparison | 1 | SEC filing |
| Nov 28, 2018 | Initial | $295,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $3K (estimated)
- Form D file number
- 021-576640
Source: Form D, filed Mar 16, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Fox | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
215 East 68 Th Street, Suite 26 B
New York, NY, 10065
New York, NY, 10065